To develop aˆlm formulation allowing controlled release for long-term analgesia, we selected ethyl cellulose (EC) as a novel additive, prepared aˆlm formulation using indomethacin (IMˆlm), and evaluated it in vitro and clinically. In the in vitro experiments, the eŠects of the EC concentration on the release rate of IM and on the adhesion force to the mucous membrane were investigated. The addition of 10％ EC resulted in more sustained slow release compared with no EC, and the adhesion of theˆlm with 10％ EC added was similar to that ofˆlms containing carboxyvinyl polymer, which we reported previously showed signiˆcantly increased adhesion. A two-layeredˆlm consisting of an adhesive layer with 2％ or 1％ IM and 10％ EC and a nonadhesive layer with 2％ polyethylene glycol as a softening agent, was investigated for clinical use. Film consisting of an adhesive layer with 2％ IM and 10％ EC exhibited rapid onset of potent analgesia and was expected to prolong the duration of analgesia. These results suggest that IMˆlm with EC added may be useful clinically, since it shows both immediate analgesic eŠects and prolonged duration of release.
INTRODUCTION
Oral mucosal pain can aŠect the activities of daily living such as eating and sleeping and may result in disorders that signiˆcantly reduce patient quality of life (QOL). In theˆeld of oral surgery, conditions involving oral pain are common, including oral mucositis, periodontal disease, tooth extraction, hemodia, and glossitis. These conditions are induced by numerous causes, such as 1) physical contact with a sharp tooth or artiˆcial denture; 2) heat injury or burns from chemical agents; 3) mucosal infection; and 4) oral mucositis or oral ulcers resulting from chemotherapy or radiation therapy.
Although oral nonsteroidal antiin‰ammatory drugs (NSAIDs) are administered to relieve pain, 1 4) there have been several reports on the risks of systemic side eŠects with oral NSAIDs, including gastrointestinal disorders. 5, 6) Thus external formulations that decrease the risk of side eŠects and allow the rapid onset of analgesia are an attractive alternative.
External formulations that relieve oral pain includê lms, sprays, 7) ointments, and mouthwashes. Film formulations can particularly improve patient QOL because of better localization and drug retention times, as well as protective coverage of the aŠected site. We previously preparedˆlm formulations containing indomethacin (IM) as an analgesic. 8) Although the novelˆlm containing carboxyvinyl polymer (CP) and polyethylene glycol (PEG) to enhance the adhesive eŠects and improve comfort, respectively, improved adhesion to the aŠected site, the formulation also showed markedly rapid drug release. Ethyl cellulose (EC) was therefore investigated in an eŠort to maintain long-term analgesic eŠects.
EC is a water-insoluble polymer used in waterproofˆlms in oral surgery, 9) is an additive in controlled-release tablets and capsules, and has been a focus of research for improving the controlled release of drugs. 10 12) Variousˆlm formulations exhibiting controlled drug release which include additives other than EC have been reported, 10 13) indicating the increasing importance of research in thisˆeld.
In this study, the eŠects of various amounts of EC inˆlm formulations on the controlled release of the drug wereˆrst investigated by monitoring IM retention. Next, other properties of EC were assessed. After storage stability had been conˆrmed, the eŠective-ness of thisˆlm formulation was evaluated in clinical use.
MATERIALS AND METHODS

Film Preparation
The layer adhering to the mucous membrane was composed of hydroxypropyl cellulose (HPC, Wako Pure Chemical Industries, Osaka, Japan) as a base component, IM (0.5％, 1％, or 2 ％) as the medication, and EC (2％, 5％, or 10％) (reagent grade, 10 cP, Wako Pure Chemical Industries) or CP (0.3％) 8) (Hivis Wako 105, Wako Pure Chemical Industries). Ingredients were dissolved in ethanol, 0.9 g of HPC was added, and then ethanol was added to give aˆnal volume of 30 ml. Using a graduated pipette with a ‰ow rate of 10 ml/4 min, 10 ml of the solution was cast in a ‰at 75-mm diameter Te‰on dish. This was followed by drying overnight on a clean bench. For the second layer, 2％ PEG 14) as a softening agent and HPC dissolved in ethanol were cast as described above. No drug precipitation was noted.
Each application was assumed to use 1 cm 2 ofˆlm with 0.5％, 1.0％, or 2.0％ IM (IM contents: 0.03 mg/ cm 2 , 0.06 mg/cm 2 , or 0.12 mg/cm 2 , respectively); 2 ％, 5％, or 10％ EC (EC contents: 0.12 mg/cm 2 , 0.3 mg/cm 2 , or 0.6 mg/cm 2 , respectively), or 0.3％ CP (CP contents: 0.036 mg/cm 2 ) and 2％ PEG (PEG content: 0.24 mg/cm 2 ). Concentrations of IM or additives were set as reported previously. 13, 15) In Vitro Release of IM Six types ofˆlm (1％ IM, 1％ IM＋2％ EC, 1％ IM＋5％ EC, 1％ IM＋10 ％ EC, 2％ IM＋5％ EC, 2％ IM＋10％ EC) were prepared and cut into circles 21 mm in diameter. A piece ofˆlm was placed in the center of a membranê lter (type HA, pore size 0.45 mm, Millipore, Billerica, MA, USA) in a vertical-diŠusion cell system (Hanson Research, Chatsworth, CA, USA)ˆlled with 15 ml of phosphate-buŠered saline (PBS) 0.1 M and kept at 37°C. The units used in this study had an eŠective diŠusion area of 21 mm in diameter and a receptor compartment volume of 15 ml. The solvent was maintained at 37°C and continuously stirred with a magnetic bar. Sample aliquots were removed through the sampling port using a syringe at 5, 10, 15, 30, 60, 120, and 360 min and replaced with an equivalent volume of fresh solvent. The amount of IM diŠusing into the collected samples was measured using an HPLC system. The HPLC system included two LC-10AD vp pumps, an SPD-10A vp ultraviolet detector, and an SIL-10AD vp autosampler (Shimadzu, Kyoto, Japan). Analysis was performed as reported previously 8) on an octadecylsilica (ODS) column (150 mm×4.6 mm i.d.) with a 5-mm particle size (Wakopak, Wakosil-II 5C18, Wako Pure Chemical Industries). The mobile phase of the assay consisted of sodium monophosphate buŠer 0.1 M and sodium acetate buŠer 0.2 M (8：2 vol/vol) at a ‰ow rate of 1.0 ml/min. Standard solutions were prepared for each assay at 0.25, 0.5, 2, 20, and 40 mg/ml.
In Vitro Adhesion Tests The experimentalˆlm consisted of three concentrations (0％, 5％, and 10 ％) of EC, 0.3％ CP as an adhesion agent, and HPC as a base component and was cut into 2-cm squares. After the experimentalˆlm was placed in the center of nonwoven cloth (4C cloth, FK900-0138 EVA80, Kuraray Kura‰ex, Tokyo, Japan) cut into 3-cm× 10-cm pieces, it was wet with 39.6 ml of PBS, folded in half, and 500 g of ‰at weight was placed on the cloth for 5 s and then removed. Five minutes after the experimentalˆlm was placed in the center of the cloth, one end of half of the cloth was pulled at a speed of 300 mm/min. The maximum force [kilogram-force (kgf)] of peeling was measured at an angle of 90°with a digital force gauge (ZP-50N, Imada, Aichi, Japan) by adjusting the slide system. The volume of PBS applied to the wet nonwoven cloth was calculated from the volume of saliva secreted in a Saxon test in aˆxed time so that it would adequately permeate the entire experimentalˆlm. 16) The experimental results were compared using ScheŠe's multiple-comparison tests.
Stability Test A 2％ IM-10％ ECˆlm formulation was prepared. Films were cut into 1-cm×1-cm pieces, packed for clinical use, and then stored under one of three conditions: at 37°C; at room temperature; and at 4°C with shading. Films were stored for 0, 7, or 28 days. The amount of IM in theˆlms was measured after dissolving in 5 ml of 0.1 M phosphoric acid buŠer solution (pH 7.0) using the HPLC system described above.
Clinical Evaluation Theˆlm composition used in the clinical evaluation is described in Table 1 . Clin- 
The three types ofˆlm were composed of two layers. Patients who had oral pain and provided written informed consent to participate were randomly allocated into three groups (control, 1％ IM, and 2％ IM) and treated in a double-blind manner. The analgesic e‹cacy of theˆlms was evaluated 1, 3, and 5 min after application. The pain ratio (X) was evaluated using the Visual Analogue Scale method, with pain before using theˆlm scored as 100％. The pain relief ratio was set at 100-X. Pain relief of 50％ or greater was judged as eŠective, while less than a 50％ reduction in pain was considered ineŠective. In addition, patients were interviewed about their degree of pain, type of pain, presence of hypoalgesia,ˆlm taste,ˆlm texture, andˆlm softness. The duration of the analgesic eŠects was set based on the time when pain recurred.
Patients who judged the experimentalˆlm as eŠective and could evaluate pain after receiving treatment at the hospital made a note of the time when oral pain was felt again. Notes were collected during the next consultation. Patients in whom the pain did not return or did not improve with initial treatment, or who could not evaluate the duration of relief due to their general medical condition, were considered unevaluable. At the next consultation, the incidence of side eŠects and treatment e‹cacy were evaluated in an interview. Pain relief ratios were compared using ScheŠe's multiple-comparison tests based on ANO-VA. This study protocol was approved by the Committee for Medicinal Products of Teikyo University Hospital.
RESULTS AND DISCUSSION
E‹cacy of EC in Controlled Drug Release IM released from the fourˆlm formulations (0％, 2％, 5 ％, and 10％ EC) was compared. At 1 and 2 h, 5％ EC and 10％ EC, respectively, showed signiˆcantly lower cumulative release of IM ( p＜0.01, Fig. 1 ). Decreased release of IM was observed with increasing EC concentration, suggesting that IM release was controlled by EC. However, the controlled release of IM would likely delay the analgesic eŠects, and thus the IM concentration in theˆlm was increased to 2％. The IM concentration was then investigated in three formulations (1％ IM, 2％ IM＋5％ EC, and 2％ IM ＋10％ EC). In the 1％ IM and 2％ IM＋10％ EC (2008) formulations, almost the same amount of IM was released at 5 and 15 min, respectively (Fig. 2) . The 2 ％ IMˆlm with EC exhibited rapid release, which was comparable to the 1％ IMˆlm formulation without EC, and was expected to have an immediate analgesic eŠect. The clinicalˆlm formulation was thus set at 10 ％ EC to minimizeˆlm hardness and 2％ IM to ensure immediate analgesic eŠects.
E‹cacy of EC in the Adhesion Test
From the results of the in vitro adhesion test,ˆlm containing 5 ％ EC, 10％ EC, and 0.3％ CP showed greater adhesion compared with controlˆlm (p＜0.01). The addition of 5％ and 10％ EC showed greater adhesion, but the adhesion was approximately the same adhesive force as 0.3％ CP, which previously showed signiˆcantly higher adhesive force (Fig. 3) , but EC was also found to increase the adhesion force.
Optimization of Storage Conditions and Expiration Date
Although decreases in IM amounts in 1 ％ IMˆlm and 2％ IMˆlm were seen after 4 weeks under all conditions examined (4°C, 99.3±1.3％ and 99.7±0.8％; room temperature, 99.8±2.3％ and 100.0±1.8％; 37°C, 98.0±1.5％ and 99.4±3.3％), the amount of IM remained at almost 100％ for 4 weeks after preparation ( Table 2) . Thus the storage conditions and expiration dates for clinical use were determined to be storage with shade, preferably in a refrigerator, for no more than 4 weeks.
Patient Background
The patients who participated in the clinical evaluation included: 16 with mucostitis; 5 with pain from surgery including tooth extraction; 11 with decubitus ulcer; 12 with injury to the oral mucous membrane (6 glossitis and 6 periodontal disease); 2 with dental caries; and 2 with xerostomia.
Clinical Evaluation Among the 48 patients, 47 were able to evaluate pain relief, and e‹cacy was noted in 72％ (34 of 47). Both IM concentrations showed good maximum pain relief ratios (1％ IM, 83.78±19.45％; 2％ IM, 93.00±11.10％).
Onset of Analgesic EŠects Both IM concentrations yielded rapid analgesic eŠects (1％ IM, 2′ 47″ ± 1′ 52″ ; 2％ IM, 1′ 58″ ±1′ 35″ ) ( Table 3 ). The rapid appearance of analgesic eŠects of both 1％ and 2％ IM was particularly marked in stomatitis (1′ 17″ ±0′ 46″ ) and decubitus ulcer (1′ 48″ ±1′ 47″ ) (data not shown).
Maximum Pain Relief by Patient Condition Maximum pain relief ratios were seen in aphtus stomatitis (98.1±4.9％), although the ratios were low for dental caries and gingivitis ( Table 4) . Changes in pain relief ratio at 1, 3, and 5 min are shown in Tables 5   and 6 .
When maximum pain relief ratios were compared by patient condition, 2％ IM showed immediate eŠects that appeared in 1 min in aphtus stomatitis and decubitus ulcer, analgesic eŠects appeared more slowly and were weaker in patients with dental caries or gingivitis.
Duration of Analgesia and Side EŠects
The duration of analgesia ranged from less than 1 to 6 h. After analgesia had been achieved, pain disappeared in 3 patients ( Table 7 ). In addition, patient reactions to theˆlms were satisfactory, with no objections toˆlm taste, texture, or softness. The duration of analgesia also showed great individual diŠerences and it was di‹cult to determine whether the prolongation of analgesia was due to the addition of EC. Therefore more examinations will be needed to determine whether the addition of EC prolongs the duration of analgesia signiˆcantly. There were few adverse events reported in clinical use and none was serious. A two-layeredˆlm comprising a 2％ IM＋10％ EC layer and a PEG layer resulted in immediate onset of analgesic eŠects and excellent clinical pain relief. The IM content of this formulation is only 1/200 of the standard oral dose and can thus likely be used in patients who are unable to receive oral analgesics, thus improving patient QOL. EC has been used in controlled-release tablets and widely studied as a release-controlling polymer. However, to the best of our knowledge, this is theˆrst report of EC used in lm formulations for application to the oral mucous membrane. The present results suggest that EC, which has moderate adhesion to the mucous membrane, exhibits both immediate drug eŠects and prolonged duration of release.
